Parklawn glasnost
Executive Summary
Soviet delegation met with FDA Drugs and Biologics staff Dec. 15 to discuss drug post-marketing surveillance and evaluation as part of a two day round of courtesty meetings with FDA and top HHS officials. Delegation was headed by Vladimir Lepakhin, MD/PhD, deputy minister of the Soviet Ministry of Public Health, responsible for approving and purchasing pharmaceuticals for the USSR. He was accompanied by Vladimir Severtsev, chief of state quality control inspections of medicines and medical equipment. FDAers present included Acting Commissioner James Benson, Stuart Nightingale, CarlPeck, Gerald Meyer, Robert Temple, James Bilstad and Gerald Faich. Also present were HHS' James Mason and U.S. Pharmacopeia Director-designate Jerome Halperin.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.